ImmunityBio, Inc.
IBRX
Classifica tra le azioni
#2195
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Prezzo delle azioni
$8.77
Capitalizzazione di mercato
$9.29B
Variazione (1 giorno)
4.12%
Variazione (1 anno)
257.82%
Paese
US
Scambia ImmunityBio, Inc. (IBRX)
Categoria
Healthcare
Ricavi di ImmunityBio, Inc. (IBRX)
Ricavi nel Jun 2026 TTM: $165.79M
Secondo gli ultimi rapporti finanziari di ImmunityBio, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $165.79M. Nel 2023, l'azienda ha registrato ricavi di $622.00K un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $240.00K. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per ImmunityBio, Inc. da 2013 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $165.79M | 1,024.39% |
| 2024 | $14.75M | 2,270.58% |
| 2023 | $622.00K | 159.17% |
| 2022 | $240.00K | -74.30% |
| 2021 | $934.00K | 54.38% |
| 2020 | $605.00K | 1,306.98% |
| 2019 | $43.00K | -8.51% |
| 2018 | $47.00K | 4.44% |
| 2017 | $45.00K | 2.27% |
| 2016 | $44.00K | -81.36% |
| 2015 | $236.00K | -63.18% |
| 2014 | $641.00K | 6.83% |
| 2013 | $600.00K | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 7,514.54% |
US
|
|
| $2.23B | 1,243.85% |
US
|
|
| $15.74B | 9,396.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 3,531.83% |
NL
|
